429 related articles for article (PubMed ID: 35777908)
1. Emerging strategies for the improvement of chemotherapy in bladder cancer: Current knowledge and future perspectives.
Liu S; Chen X; Lin T
J Adv Res; 2022 Jul; 39():187-202. PubMed ID: 35777908
[TBL] [Abstract][Full Text] [Related]
2. Current Therapy for Metastatic Urothelial Carcinoma.
Nadal R; Clara JA; Valderrama BP; Bellmunt J
Hematol Oncol Clin North Am; 2021 Jun; 35(3):469-493. PubMed ID: 33958146
[TBL] [Abstract][Full Text] [Related]
3. The emerging role of antibody-drug conjugates in urothelial carcinoma.
Lattanzi M; Rosenberg JE
Expert Rev Anticancer Ther; 2020 Jul; 20(7):551-561. PubMed ID: 32552213
[TBL] [Abstract][Full Text] [Related]
4. The Rapidly Evolving Landscape of First-Line Targeted Therapy in Metastatic Urothelial Cancer: A Systematic Review.
Lavoie JM; Sridhar SS; Ong M; North S; Alimohamed N; McLeod D; Eigl BJ
Oncologist; 2021 Aug; 26(8):e1381-e1394. PubMed ID: 34028134
[TBL] [Abstract][Full Text] [Related]
5. [Antibody-drug conjugates as new therapeutic agents in uro-oncology].
Grimm MO; Foller S; Leeder M; Leucht K
Urologie; 2023 Jul; 62(7):679-684. PubMed ID: 37294330
[TBL] [Abstract][Full Text] [Related]
6. Evolving systemic management of urothelial cancers.
Tan WS; Tan MY; Alhalabi O; Campbell MT; Kamat AM; Gao J
Curr Opin Oncol; 2023 May; 35(3):186-199. PubMed ID: 36966497
[TBL] [Abstract][Full Text] [Related]
7. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
8. [Innovations in systemic treatment of urothelial carcinoma].
Thibault C; Gross-Goupil M
Bull Cancer; 2020 Jun; 107(5S):S6-S16. PubMed ID: 32620209
[TBL] [Abstract][Full Text] [Related]
9. Urothelial carcinoma in the era of immune checkpoint inhibitors.
Khalife N; Chahine C; Kordahi M; Felefly T; Kourie HR; Saleh K
Immunotherapy; 2021 Aug; 13(11):953-964. PubMed ID: 34184561
[TBL] [Abstract][Full Text] [Related]
10. An update on antibody-drug conjugates in urothelial carcinoma: state of the art strategies and what comes next.
D'Angelo A; Chapman R; Sirico M; Sobhani N; Catalano M; Mini E; Roviello G
Cancer Chemother Pharmacol; 2022 Sep; 90(3):191-205. PubMed ID: 35953604
[TBL] [Abstract][Full Text] [Related]
11. New and Emerging Therapies in the Management of Bladder Cancer.
Osterman CK; Milowsky MI
F1000Res; 2020; 9():. PubMed ID: 32983413
[TBL] [Abstract][Full Text] [Related]
12. Systemic therapy in muscle-invasive and metastatic bladder cancer: current trends and future promises.
Aragon-Ching JB; Trump DL
Future Oncol; 2016 Sep; 12(17):2049-58. PubMed ID: 27306417
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions.
Tripathi A; Plimack ER
Curr Urol Rep; 2018 Nov; 19(12):109. PubMed ID: 30406502
[TBL] [Abstract][Full Text] [Related]
14. Emerging strategy for the treatment of urothelial carcinoma: Advances in antibody-drug conjugates combination therapy.
You X; Zhu C; Yu P; Wang X; Wang Y; Wang J; Yu J; Wang K
Biomed Pharmacother; 2024 Feb; 171():116152. PubMed ID: 38228034
[TBL] [Abstract][Full Text] [Related]
15. Complete Response With Immunotherapy: A Case of Metastatic Bladder Cancer.
Singh B; Kaur P; Gupta S; Guragai N; Maroules M
J Investig Med High Impact Case Rep; 2021; 9():23247096211035603. PubMed ID: 34308703
[TBL] [Abstract][Full Text] [Related]
16. Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer.
Katz H; Wassie E; Alsharedi M
Med Oncol; 2017 Sep; 34(10):170. PubMed ID: 28864844
[TBL] [Abstract][Full Text] [Related]
17. Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder.
Rouanne M; Bajorin DF; Hannan R; Galsky MD; Williams SB; Necchi A; Sharma P; Powles T
Eur Urol Oncol; 2020 Dec; 3(6):728-738. PubMed ID: 33177001
[TBL] [Abstract][Full Text] [Related]
18. Fibroblast Growth Factor Inhibitors for Treating Locally Advanced/Metastatic Bladder Urothelial Carcinomas via Dual Targeting of Tumor-Specific Oncogenic Signaling and the Tumor Immune Microenvironment.
Lee HW; Seo HK
Int J Mol Sci; 2021 Sep; 22(17):. PubMed ID: 34502435
[TBL] [Abstract][Full Text] [Related]
19. Insights on recent innovations in bladder cancer immunotherapy.
Abd El-Salam MA; Smith CEP; Pan CX
Cancer Cytopathol; 2022 Sep; 130(9):667-683. PubMed ID: 35653623
[TBL] [Abstract][Full Text] [Related]
20. A novel strategy for treatment of bladder cancer: Antibody-drug conjugates.
Kim JH; Chang IH
Investig Clin Urol; 2022 Jul; 63(4):373-384. PubMed ID: 35670004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
